Dietrich Keppler

Title: Dietrich Keppler: Innovator in Transport Inhibitors and Tumor Resistance

Introduction

Dietrich Keppler is a notable inventor based in Dossenheim, Germany. He has made significant contributions to the field of biomedical research, particularly in the identification of transport inhibitors and methods for treating resistant tumors. With a total of 3 patents, his work has implications for drug development and cancer treatment.

Latest Patents

Keppler's latest patents include a double-transfected cell line useful for the identification of transport inhibitors. This invention describes a cell line containing a DNA sequence encoding an uptake transporter for organic anions, preferably OATP8, and an export pump for organic anions or anionic conjugates, preferably the multidrug resistance protein 2 (MRP2). The cell line is designed for identifying transport inhibitors, which can serve as potential drug candidates. Another significant patent involves methods for identifying and treating resistant tumors. This invention provides a method for identifying and reversing multidrug resistance in tumors by administering a multidrug resistance reversing amount of specific compounds.

Career Highlights

Throughout his career, Dietrich Keppler has worked with prominent organizations, including the Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts and Eli Lilly and Company. His experience in these institutions has allowed him to advance his research and contribute to the scientific community.

Collaborations

Keppler has collaborated with notable colleagues such as Gabriele Jedlitschky and Inka Leier. These partnerships have further enriched his research endeavors and expanded the impact of his inventions.

Conclusion

Dietrich Keppler's innovative work in the field of transport inhibitors and tumor resistance showcases his dedication to advancing medical science. His patents and collaborations reflect a commitment to improving drug development and cancer treatment.